GLUE
Price
$4.91
Change
-$0.01 (-0.20%)
Updated
Jun 13 closing price
Capitalization
302.01M
54 days until earnings call
MEIP
Price
$2.29
Change
+$0.03 (+1.33%)
Updated
Jun 13 closing price
Capitalization
15.26M
Interact to see
Advertisement

GLUE vs MEIP

Header iconGLUE vs MEIP Comparison
Open Charts GLUE vs MEIPBanner chart's image
Monte Rosa Therapeutics
Price$4.91
Change-$0.01 (-0.20%)
Volume$380.74K
Capitalization302.01M
MEI Pharma
Price$2.29
Change+$0.03 (+1.33%)
Volume$5.28K
Capitalization15.26M
GLUE vs MEIP Comparison Chart
Loading...
GLUE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MEIP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GLUE vs. MEIP commentary
Jun 14, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GLUE is a StrongBuy and MEIP is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 14, 2025
Stock price -- (GLUE: $4.91 vs. MEIP: $2.29)
Brand notoriety: GLUE and MEIP are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GLUE: 68% vs. MEIP: 71%
Market capitalization -- GLUE: $302.01M vs. MEIP: $15.26M
GLUE [@Biotechnology] is valued at $302.01M. MEIP’s [@Biotechnology] market capitalization is $15.26M. The market cap for tickers in the [@Biotechnology] industry ranges from $355.9B to $0. The average market capitalization across the [@Biotechnology] industry is $2.45B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GLUE’s FA Score shows that 1 FA rating(s) are green whileMEIP’s FA Score has 0 green FA rating(s).

  • GLUE’s FA Score: 1 green, 4 red.
  • MEIP’s FA Score: 0 green, 5 red.
According to our system of comparison, MEIP is a better buy in the long-term than GLUE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GLUE’s TA Score shows that 6 TA indicator(s) are bullish while MEIP’s TA Score has 5 bullish TA indicator(s).

  • GLUE’s TA Score: 6 bullish, 4 bearish.
  • MEIP’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, both GLUE and MEIP are a good buy in the short-term.

Price Growth

GLUE (@Biotechnology) experienced а -2.00% price change this week, while MEIP (@Biotechnology) price change was +5.01% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.63%. For the same industry, the average monthly price growth was +13.05%, and the average quarterly price growth was +4.06%.

Reported Earning Dates

GLUE is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (-0.63% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GLUE($302M) has a higher market cap than MEIP($15.3M). GLUE has higher P/E ratio than MEIP: GLUE (40.92) vs MEIP (1.09). MEIP YTD gains are higher at: -6.911 vs. GLUE (-29.251). GLUE has higher annual earnings (EBITDA): 6.14M vs. MEIP (-22.17M). GLUE has more cash in the bank: 326M vs. MEIP (20.5M). MEIP has less debt than GLUE: MEIP (11.7M) vs GLUE (41.9M). GLUE has higher revenues than MEIP: GLUE (159M) vs MEIP (0).
GLUEMEIPGLUE / MEIP
Capitalization302M15.3M1,974%
EBITDA6.14M-22.17M-28%
Gain YTD-29.251-6.911423%
P/E Ratio40.921.093,741%
Revenue159M0-
Total Cash326M20.5M1,590%
Total Debt41.9M11.7M358%
FUNDAMENTALS RATINGS
MEIP: Fundamental Ratings
MEIP
OUTLOOK RATING
1..100
12
VALUATION
overvalued / fair valued / undervalued
1..100
57
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
98
PRICE GROWTH RATING
1..100
59
P/E GROWTH RATING
1..100
39
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
GLUEMEIP
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
89%
Bullish Trend 2 days ago
74%
MACD
ODDS (%)
Bullish Trend 2 days ago
89%
N/A
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
72%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
69%
Advances
ODDS (%)
Bullish Trend 18 days ago
87%
Bullish Trend 4 days ago
71%
Declines
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 18 days ago
83%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
79%
Aroon
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
59%
View a ticker or compare two or three
Interact to see
Advertisement
GLUE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MEIP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FSMVX28.80N/A
N/A
Fidelity Mid Cap Value
GEORX6.33-0.08
-1.25%
Pear Tree Essex Environmental Opps R6
EQNAX21.81-0.28
-1.27%
MFS Equity Income A
JGINX72.64-0.98
-1.33%
Janus Henderson Growth And Income I
GSTRX9.58-0.13
-1.34%
Goldman Sachs Strategic Growth R

GLUE and

Correlation & Price change

A.I.dvisor indicates that over the last year, GLUE has been loosely correlated with EYPT. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if GLUE jumps, then EYPT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GLUE
1D Price
Change %
GLUE100%
-0.20%
EYPT - GLUE
48%
Loosely correlated
+1.92%
CRSP - GLUE
43%
Loosely correlated
+0.19%
IMNM - GLUE
43%
Loosely correlated
-6.03%
ATXS - GLUE
43%
Loosely correlated
+2.14%
FATE - GLUE
42%
Loosely correlated
-8.93%
More

MEIP and

Correlation & Price change

A.I.dvisor tells us that MEIP and DNLI have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that MEIP and DNLI's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MEIP
1D Price
Change %
MEIP100%
+1.33%
DNLI - MEIP
29%
Poorly correlated
-2.51%
NRIX - MEIP
26%
Poorly correlated
-0.25%
FBIO - MEIP
26%
Poorly correlated
-5.61%
GLUE - MEIP
26%
Poorly correlated
-0.20%
MNMD - MEIP
25%
Poorly correlated
-1.78%
More